Recent Company News

• 08:07 AM ET Jun 22, 2026
  

  Verrica Pharmaceuticals announces first U.S. patient dosed in the second pivotal clinical trial (COVE-3) of Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts ($5.63, 0.00)

• 01:03 AM ET Jun 19, 2026
  

  Shionogi & Co. receives supplemental approval in Japan for pediatric dosage and administration of XOCOVA (¥2771.5000, -61.5)

• 12:04 AM ET Jun 18, 2026
  

  Shionogi & Co. reports global phase 3 OASIS study evaluating oral Olorofim versus AmBisome achieves primary endpoint (¥2848.5000, +16)

• 03:40 AM ET Jun 15, 2026
  

  Goldman Sachs upgrades 4507.JP, 4519.JP

• 08:59 AM ET Jun 01, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:18 PM ET May 29, 2026
  

  FDA approves Xocova (ensitrelvir) to treat COVID-19 (¥3000.0000, 0)

• 02:11 PM ET May 29, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 31-May

• 02:07 AM ET May 29, 2026
  

  Shionogi & Co. receives China NPMA approval for Naldemedine for treatment of opioid-induced constipation (¥3022.0000, +25.5)

• 05:37 PM ET May 13, 2026
  

  Shionogi & Co. publishes results from SCORPIO-PEP Phase 3 study for ensitrelvir in New England Journal of Medicine (¥2978.0000, 0)

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Guidance